Gastric cancer: trastuzumab trial results spur search for other targets.

Journal of the National Cancer Institute

Volumn 101, Issue 19, 2009, Pages 1306-1307

  Hede, Karyn ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; HEAT SHOCK PROTEIN 90; HER2 PROTEIN, HUMAN; LAPATINIB; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; RAPAMYCIN; TRASTUZUMAB; TUMOR MARKER;

CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; MORTALITY; MULTICENTER STUDY (TOPIC); NOTE; STOMACH TUMOR; SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MULTICENTER STUDIES AS TOPIC; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIROLIMUS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77950859162     PISSN: None     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp341     Document Type: Note

References (0)